Protective effects of fasudil hydrochloride post-conditioning on acute myocardial ischemia/reperfusion injury in rats

Cardiology Journal

Volumn 20, Issue 2, 2013, Pages 197-202

  Jiang, Zhi hui ^a   Zhang, Tian tian ^a   Zhang, Jun Feng ^a  

^a School of Medicine   (China)

Author keywords

Fasudil hydrochloride (FH); Ischemia reperfusion; Post conditioning

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; FASUDIL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 1; RHO KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION SIZE; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; DISEASE MODELS, ANIMAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84885237027     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0034     Document Type: Article

References (27)

1. Ting P, Chua TS, Wong A, Sim LL, Tan VW, Koh TH. Trends in mor- tality from acute myocardial infarction in the coronary care unit. Ann Acad Med Singapore, 2007; 36: 974-979.
2. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther, 2011; 5: 325-380.
3. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistic-2008 update: A report from the American Heart Association Statistics Committee and Stroke Subcommittee. Circulation, 2008; 117: e25-e146.
4. Sanz-Rosa D, García-Prieto J, Ibanez B. The future: Therapy of myo- cardial protection. Ann NY Acad Sci, 2012; 1254: 90-98.
5. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation, 1986; 74: 1124-1136.
6. Zhao ZQ, Corvera JS, Halkos ME et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol, 2003; 285: H579-H588.
7. Yang XC, Liu Y, Wang LF et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary inter-vention. J Invasive Cardiol, 2007; 19: 424-430.
8. Thibault H, Piot C, Staat P et al. Long-term benefit of postcondition-ing. Circulation, 2008; 117: 1037-1044.
9. Heusch G, Boengler K, Schulz R. Cardioprotection: Nitric oxide, pro-tein kinases, and mitochondria. Circulation, 2008; 118: 1915-1919.
10. Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res, 2000; 87: 309-315.
11. Tissier R, Waintraub X, Couvreur N et al. Pharmacological postcon-ditioning with the phytoestrogen genistein. J Mol Cell Cardiol, 2007; 42: 79-87.
12. Del Re DP, Miyamoto S, Brown JH. RhoA/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyo-cyte apoptosis. J Biol Chem, 2007; 282: 8069-8078.
13. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med, 2007; 357: 1121-1135.
14. Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol, 2003; 15: 691-699.
15. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: Taking a RISK for cardioprotection. Heart Fail Rev, 2007; 12: 217-234.
16. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. Heart Fail Rev, 2007; 12: 181-188.
17. Tissier R, Berdeaux A, Ghaleh B et al. Making the heart resistant to infarction: How can we further decrease infarct size? Front Biosci, 2008; 13: 284-301.
18. Hamid SA, Bower HS, Baxter GF. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myo-cardium. AM J Physiol Heart Circ Physiol, 2007; 292: H2598-H606.
19. Wolfrum S, Dendorfer A, Rikitake Y et al. Inhibition of Rho kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein ki- nase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol, 2004; 24: 1842-1847.
20. Jacobs M, Hayakawa K, Swenson L et al. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem, 2006; 281: 260-268.
21. Ichinomiya T, Cho S, Higashijima U, Matsumoto S, Maekawa T, Sumikawa K. High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: Role of mitochon- drial KATP channels. Cardiovasc Diabetol, 2012; 11: 28.
22. Zhang YM, Wang Y, Liu XH, Zhang DW. Cardioprotective effect of edaravone pharmacological postconditioning on acute myocardial is- chemia/reperfusion injury: Experiment with rats. Zhonghua Yi Xue Za Zhi, 2008; 88: 2558-2561.
23. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest, 1994; 94: 1621-1628.
24. Fliss H, Gattinger D. Apotosis in ischemic and reperfused rat myo-cardium. Circ Res, 1996; 79: 949-956.
25. Beresewicz A, Czarnowska E, Maczewski M. Ischemic preconditioning and superoxide dismutase protect against endothelial dysfunction and endothelium glycocalyx disruption in the postischemic guinea-pig hearts. Mol Cell Biochem, 1998; 186: 87-97.
26. Matsui T, Amano M, Yamamoto T et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J, 1996; 15: 2208-2216.
27. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mito-chondrial permeability transition pore opening: A new paradigm for myocardial preconditioning? Cardiovasc Res, 2002; 55: 534-543.